MX2015017535A - Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4. - Google Patents

Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.

Info

Publication number
MX2015017535A
MX2015017535A MX2015017535A MX2015017535A MX2015017535A MX 2015017535 A MX2015017535 A MX 2015017535A MX 2015017535 A MX2015017535 A MX 2015017535A MX 2015017535 A MX2015017535 A MX 2015017535A MX 2015017535 A MX2015017535 A MX 2015017535A
Authority
MX
Mexico
Prior art keywords
treatment
tsc22d4
insulin resistance
inhibitors
transcription factor
Prior art date
Application number
MX2015017535A
Other languages
English (en)
Other versions
MX364003B (es
Inventor
BERRIEL DIAZ Mauricio
Herzig Stephan
Friedrich Kilian
Jones Allan
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Publication of MX2015017535A publication Critical patent/MX2015017535A/es
Publication of MX364003B publication Critical patent/MX364003B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Abstract

Se refiere la presente invención a moduladores, en particular inhibidores, de la actividad o expresión de TSC22D4 y sus usos para la prevención, tratamiento y/o regulación de la resistencia a la insulina, síndrome metabólico y/o diabetes y/o para mejorar la sensibilidad a la insulina en mamíferos. La presente invención se refiere además a métodos de evaluación para identificar estos moduladores, el uso de moduladores como se identifica en el diagnóstico de estas enfermedades, así como kits, que comprenden los materiales para llevar a cabo los métodos de acuerdo con la presente invención.
MX2015017535A 2013-06-17 2014-06-17 Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4. MX364003B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130172362 EP2816356A1 (en) 2013-06-17 2013-06-17 Treatment of insulin resistance through inhibitors of transcription factor TSC22D4
PCT/EP2014/062713 WO2014202602A1 (en) 2013-06-17 2014-06-17 Treatment of insulin resistance through inhibitors of transcription factor tsc22d4

Publications (2)

Publication Number Publication Date
MX2015017535A true MX2015017535A (es) 2016-08-08
MX364003B MX364003B (es) 2019-04-10

Family

ID=48625934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017535A MX364003B (es) 2013-06-17 2014-06-17 Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.

Country Status (10)

Country Link
US (1) US9879258B2 (es)
EP (2) EP2816356A1 (es)
JP (1) JP6479780B2 (es)
KR (1) KR102401450B1 (es)
CN (1) CN105247371B (es)
CA (1) CA2908889C (es)
DK (1) DK3011341T3 (es)
ES (1) ES2733555T3 (es)
MX (1) MX364003B (es)
WO (1) WO2014202602A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072969A1 (en) 2015-03-23 2016-09-28 DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗
CN112956453B (zh) * 2021-04-07 2022-10-11 华北理工大学 一种黑腹果蝇胰岛素抵抗糖尿病模型的建立方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703625A (zh) * 2002-08-06 2005-11-30 法赫马西亚及普强有限公司 果蝇g蛋白偶联受体,核酸和相关方法
JP4869942B2 (ja) * 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
WO2012061754A2 (en) * 2010-11-05 2012-05-10 The Broad Institute, Inc. Compounds and methods for treating autoimmune diseases
SG194909A1 (en) * 2011-05-13 2013-12-30 Agency Science Tech & Res Compounds and methods for treating insulin resistance syndrome
CN102311952A (zh) * 2011-09-19 2012-01-11 中南大学 一种多癌风险易感性突变位点及其应用和制备的试剂盒
GB201120317D0 (en) * 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method

Also Published As

Publication number Publication date
US20160115475A1 (en) 2016-04-28
JP6479780B2 (ja) 2019-03-06
ES2733555T3 (es) 2019-11-29
CN105247371A (zh) 2016-01-13
KR20160021106A (ko) 2016-02-24
MX364003B (es) 2019-04-10
CA2908889C (en) 2022-07-26
KR102401450B1 (ko) 2022-05-24
US9879258B2 (en) 2018-01-30
DK3011341T3 (da) 2019-07-22
CA2908889A1 (en) 2014-12-24
WO2014202602A1 (en) 2014-12-24
EP3011341B1 (en) 2019-04-10
CN105247371B (zh) 2019-01-11
EP3011341A1 (en) 2016-04-27
JP2016532098A (ja) 2016-10-13
WO2014202602A9 (en) 2015-12-23
EP2816356A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2016002987A (es) Biomarcadores de expresion de genes con sensibilidad a laquinimod.
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
EA201490559A1 (ru) Композиция для лечения свища
MX2015009276A (es) Donadores de nitroxilo con indice terapeutico mejorado.
DK3065764T6 (da) Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling
BR112014029301A2 (pt) métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP2967060A4 (en) METHODS OF DIAGNOSING, SELECTING AND TREATING DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENIC BACTERIA
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
WO2015069883A8 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
TR201900665T4 (tr) Diyabetik nefropatinin tedavi yöntemi.
WO2014195847A3 (en) Uses of stable isotope labeled l-tryptophan
MX371426B (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
BR112016004450A2 (pt) métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor

Legal Events

Date Code Title Description
FG Grant or registration